QGEN

QIAGEN N.V. provides sample and assay technologies for molecular diagnostics, applied testing, pharmaceutical research, and academic research. Headquartered in Venlo, the Netherlands, with operational headquarters in Hilden, Germany, the company operates in more than 35 locations worldwide and employs approximately 6,000 people. QIAGEN's product portfolio includes sample preparation technologies that isolate and process DNA, RNA, and proteins from biological samples, as well as assay technologies for analyzing molecular biomarkers. The company serves customers across five major customer classes: molecular diagnostics, applied testing (including forensics and veterinary testing), pharmaceutical and biotechnology companies, and academia. QIAGEN holds leadership positions in sample preparation and PCR-based assays, with over 500,000 customers globally. The company generated approximately $2.2 billion in annual revenue as of 2023. Key product franchises include the QIAstat-Dx respiratory panel, QuantiFERON tuberculosis testing, and next-generation sequencing sample preparation kits. QIAGEN has strengthened its portfolio through strategic acquisitions, including STAT-Dx and NeuMoDx Molecular for molecular diagnostics automation. The company operates through a direct sales force in major markets and distributors in smaller territories, maintaining manufacturing facilities in Germany, the United States, and China. QIAGEN's business model combines consumable products, which generate recurring revenue, with instrumentation platforms.